Tuesday, October 13, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 3, 2026

Stock market today: Nasdaq, S&P 500 slide as investors digest flood of tech earnings, government shutdown

View original at finance.yahoo.com
Stock market today: Nasdaq, S&P 500 slide as investors digest flood of tech earnings, government shutdown US stocks slid Tuesday investors digested a wave of tech-focused earnings, precious metals jumped to continue their wild ride, and a partial government shutdown rolled into its fourth day…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Throughout 2025, NXP executed effectively despite challenging first half, maintaining operational discipline while advancing strategic priorities in software defined vehicles and physical AI

    80% confidence

  • Downplayed OpenAI investment plan of up to $100 billion

    80% confidence

  • Remains on track to deliver 133MW of critical IT load to CoreWeave in first half of 2026

    80% confidence

  • Raised SanDisk price target to $1,000 from $580 and maintained Outperform rating

    80% confidence

  • Walmart could benefit from tax refund provisions in the One Big Beautiful Bill Act

    80% confidence

  • Sales decline attributed to continued volume penetration from GLP-1 treatments, market expansion in obesity, intensifying competition, and compound patent expiry of semaglutide molecule

    80% confidence

  • Received ERCOT approval for additional 830 MW of power capacity, bringing Helios total approved capacity to more than 1.6 gigawatts

    80% confidence

  • Raised Walmart price target to $130 on company's apparel strength

    80% confidence

  • The structural shortage in memory chips makes the continued growth of Samsung and SK Hynix inevitable

    80% confidence

  • Digital assets trading volumes declined by approximately 40% quarter-on-quarter, reflecting softer client activity following record Q3

    80% confidence

  • Venezuela is uninvestable in its current state

    80% confidence

  • Due to partial federal government shutdown, BLS will suspend data collection, processing, and dissemination

    80% confidence

  • US sales impact due to current prescription trends for injectable GLP-1 portfolio, intensifying competition, and negative impact from reduced obesity medication coverage in Medicaid

    80% confidence

  • Q4 loss reflects softer macro environment and lower industry trading volumes and onchain activity

    80% confidence

  • JOLTS, Metropolitan Area Employment and Unemployment, and Employment Situation releases will be rescheduled upon resumption of government funding

    80% confidence

Data points we hold from this source

Novo Nordisk A/S · forecast operating profit decline-5 to -13 percent
Novo Nordisk A/S · forecast sales decline-5 to -13 percent
Novo Nordisk A/S · daily stock change-14 percent
Walmart Inc. · market cap1 trillion_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com
Stock market today: Nasdaq, S&P 500 slide as investors digest flood of tech earnings, government shutdown — Source | Via News | Via News